Treatment

Patient Input Needed: Clinical Trial Design

July 5, 2018 | Categories: Research, Treatment

As part of their Commitment to Patients and Caregivers, our partners at Novartis are working to make the clinical trial experience more patient-centric and widely accessible. To this goal, they are currently seeking melanoma patients who have participated in a clinical trial in the past two years and who are interested in serving on an advisory board.

What's Next: 

Trial participants invited to "Meet the Scientist" in Denver, attend MRF Gala

March 20, 2018 | Categories: Events, Treatment

Meet the Scientist: Your Chance to Speak with the Mind Behind the COLUMBUS Phase 3 Trial in BRAF-Mutant Melanoma

January 2, 2018 | Categories: News, Research, Treatment

Make a Difference with Wayne and the MRF

December 19, 2017 | Categories: Causes, Patient Stories, Treatment

Wayne ConnersGuest blog post by melanoma survivor and MRF volunteer advocate, Wayne Conners:

FDA Expands Approval of Ipilimumab For Pediatric Melanoma Patients

August 3, 2017 | Categories: News, Research, Treatment

Last week the United States Food and Drug Administration (FDA) expanded approval of Yervoy (ipilimumab) to include pediatric patients ages 12 years and older with unresectable or metastatic melanoma. Yervoy, a monoclonal antibody that activates the immune system by blocking the CTLA-4 receptor, was first approved in 2011 to treat unresectable or metastatic melanoma in adults.

The New York Times & Cancer Survival

January 16, 2014 | Categories: Treatment

The MRF's Executive Director shares his thoughts on the recent controversy involving a New York Times' editor and his criticism of breast cancer patient Lisa Adams.

The Many Faces of Melanoma

March 26, 2013 | Categories: Treatment

We’ve heard the story before: a woman is treated successfully for her melanoma, only to have the cancer come back after ten years. How? Why? One explanation is something called “tumor heterogeneity.”

Expanding Knowledge

March 4, 2013 | Categories: Treatment

I recently met with a company called Delcath, which has a procedure designed to combat metastases to the liver. It works by infusing high doses of chemotherapy directly into the liver through the bloodstream. As the blood exits the liver, it is shunted outside the body and run through special filters that remove the majority of the toxic chemotherapy compound. The blood then goes back into the body’s general circulation.

Knowledge is Power

February 12, 2013 | Categories: Treatment

Yesterday, the MRF hosted a live webinar focusing on how to manage melanoma treatment in a rapidly changing landscape. As we prepared for the webinar, I heard disturbing stories of many patients receiving care that is sloppy, outdated, or just wrong:

FDA to Consider Patient Perspective in Drug Development

November 8, 2012 | Categories: News, Treatment, Research

The FDA is launching a new program in which they will consider and incorporate the patient perspective into drug development.  They will choose 20 diseases for the program and the MRF is lobbying to have melanoma be one of them.  As we all know, the patient perspective is important in any disease, but it is especially true with melanoma. 

Here is my letter to the FDA expressing this great need in the field of melanoma.

Pages